Dr. Michael Triebwasser


Michael received his bachelor's degree in molecular biology from the University of Wisconsin in 2005. He then spent a year studying bioinformatics in Brasenose College at the University of Oxford.  He went on to earn his MD/PhD from Washington University in St Louis in 2015, where his graduate work was in developing targeted sequencing assays and applying them to large populations to identify rare variants or large effect. He went on to complete his pediatrics training at the University of Michigan. He joined the CHOP Hematology/Oncology fellowship in 2018. Michael joined the Rivella lab in the summer of 2019 with an interest in gene therapy for nonmalignant diseases. Specifically, he is interested in developing alternative conditioning regiments that use immunotherapies in contrast to myeloablative  chemotherapy. This would serve as a less toxic conditioning regiment to expand access to gene therapies already in development. He is also interested in the use of gene therapy for immunodeficiencies and is working to implement a lentiviral based strategy.